The purpose of this study is to examine the efficacy and safety of Ivermectin in the prevention of COVID 19 following exposure and to determine the number of participants who will develop clinical COVID-19. 1)The Primary outcome measure is the onset of clinical disease(symptoms such as Fever ;Cough; Sore Throat; Myalgia; Diarrhea; Shortness of Breath within 14 days after enrollment. subsequently confirmed by RT-PCR(New infection)2).Number developing COVID-19 clinical disease

The purpose of this study is to examine the efficacy and safety of Ivermectin in the prevention of COVID 19 following exposure and to determine the number of participants who will develop clinical COVID-19. 1)The Primary outcome measure is the onset of clinical disease(symptoms such as Fever ;Cough; Sore Throat; Myalgia; Diarrhea; Shortness of Breath within 14 days after enrollment. subsequently confirmed by RT-PCR(New infection)2).Number developing COVID-19 clinical disease